A history of streptokinase use in acute myocardial infarction

Texas Heart Institute Journal

Volumn 34, Issue 3, 2007, Pages 318-327

  Sikri, Nikhil ^a   Bardia, Amit ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acute myocardial infarction; GISSI; History of medicine, 20th century; Sol Sherry; Streptokinase; W.S. Tillett

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; DICOUMAROL; HEPARIN; PLASMINOGEN ACTIVATOR; RETEPLASE; STREPTOKINASE; TENECTEPLASE; WARFARIN;

ACUTE HEART INFARCTION; ARTHRALGIA; BLEEDING; CLINICAL TRIAL; FEVER; HEADACHE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; MALAISE; MORTALITY; NAUSEA; NONHUMAN; REPERFUSION; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARDIOLOGY; FIBRINOLYTIC AGENTS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; INFUSIONS, INTRAVENOUS; MYOCARDIAL INFARCTION; PORTRAITS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 35848965673     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Braunwald E. Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 1998;352:1771-4.
2. Heberden W. Some account of a disorder of the breast. Med Trans Coll Physicians London 1772;2:59-67.
3. Weigert C. Ueber die pathologiische Gerinnugs-Vorgange. Arch Path Anat (Virchow) 1880;79:87-123.
4. Landmark article (JAMA 1912). Clinical features of sudden obstruction of the coronary arteries. By James B. Herrick. JAMA 1983;250:1757-65.
5. Parkinson J, Bedford E. Cardiac infarction and coronary thrombosis. Lancet 1928;1:4-11.
6. Craven LL. Acetylsalicylic acid: possible preventive of coronary thrombosis. Ann West Med Surg 1950;4:95-9.
7. Craven LL. Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J 1953;75:38-44.
8. Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956;78:213-5.
9. Julian DG. Treatment of cardiac arrest in acute myocardial ischaemia and infarction. Lancet 1961;2:840-4.
10. Nichol ES, Page SW. Dicumarol therapy in acute coronary thrombosis; results in fifty attacks, with review of data on embolic complications and immediate mortality in myocardial infarction. J Fla Med Assoc 1946;32:365-70.
11. Wright IS. Experience with dicumarol in the treatment of coronary thrombosis with myocardial infarction. Preliminary report. Am Heart J 1946;32:20-31.
12. Wright IS, Marple CD, Beck DF. Report of the committee for the evaluation of anticoagulants in the treatment of coronary thrombosis with myocardial infarction. Am Heart J 1948;36:801-15.
13. Hilden T, Iversen K, Raaschou F, Schwartz M. Anticoagulants in acute myocardial infarction. Lancet 1961;2:327-31.
14. Wasserman AJ, Gutterman LA, Yoe KB, Kemp VE Jr, Richardson DW. Anticoagulants in acute myocardial infarction. The failure of anticoagulants to alter mortality in a randomized series. Am Heart J 1966;71:43-9.
15. Assessment of short-anticoagulant administration after cardiac infarction. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. Br Med J 1969;1:335-42.
16. Miller HS Jr. Sodium heparin vs sodium warfarin in acute myocardial infarction; conclusions based on study of 798 cases at 13 hospitals. JAMA 1964;189:555-62.
17. Eastman GL, Cook ET, Shinn ET, Dutton RE, Lyons RH. A clinical study of anticoagulants in acute myocardial infarction with particular reference to early heparin therapy. Am J Med Sci 1957;233:647-53.
18. Nordoey S, Benestad AM. Evaluation of the effect of heparin in addition to oral anticoagulant therapy in acute myocardial infarction. Acta Med Scand 1963;174:627-34.
19. Sherry S. Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. Am Heart J 1981;102(6 Pt 2):1134-8.
20. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933;58:485-502.
21. Tillett WS, Edwards LB, Garner RL. Fibrinolytic activity of hemolytic streptococci. The development of resistance to fibrinolysis following acute hemolytic streptococcus infections. J Clin Invest 1934;13:47-78.
22. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: I. Isolation and characterization of fibrinolysin. J Exp Med 1934;60:239-54.
23. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: II. Nature of the reaction. J Exp Med 1934;60:255-67.
24. Tillett WS. The fibrinolytic activity of hemolytic streptococci in relation to the source of strains and to cultural reactions. J Bacteriol 1935;29:111-30.
25. Tillett WS. The occurrence of antifibrinolytic properties in the blood of patients with acute hemolytic streptococcus infections. J Clin Invest 1935;14:276-84.
26. Le Mar JD, Gunderson MF. Studies on streptococcal fibrinolysis. J Bacteriol 1940;39:717-25.
27. Tillett WS. The fibrinolytic activity of hemolytic streptococci. Bacteriol Rev 1938;2:161-216.
28. Van Deventer JK, Reich T. Antihuman fibrinolytic streptococci. Proc Soc Exp Biol Med 1934;31:821-2.
29. Planet N. Sur l'action fibrinolytique des streptocoques hemolytiques d'origine equine. Compt Rend Soc Biol 1935;120:169-72.
30. Garner RL. Fibrinolytic enzyme of hemolytic streptococci. J Biol Chem 1935;109:36-7.
31. Schmidt H. Beitrage zur kenntnis der hemolytischen streptokokken und der eigenschaften des antistreptokokkenserums die fibrinolyse der streptokokken. Z Immunitats 1936;87:1-8.
32. Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol 1941;42:109-16.
33. Christensen LR. The mechanism of streptococcal fibrinolysis [abstract]. J Bact 1944;47:471-2.
34. Christensen LR. Streptococcal fibrinolysis: a proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysin. J Gen Physiol 1945;28:363-83.
35. Kaplan MH. Nature and role of lytic factor in hemolytic streptococcal fibrinolysis. Proc Soc Exp Biol Med 1944;57:40-3.
36. Christensen LR, MacLeod CM. A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J Gen Physiol 1945;28:559-83.
37. Evans AC. Studies on hemolytic streptococci: VIII. Streptococcus equisimilis. J Bacteriol 1944;48:267-84.
38. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J Clin Invest 1949;28:173-90.
39. Sherry S, Tillett WS, Read CT. The use of streptokinase-streptodornase in the treatment of hemothorax. J Thorac Surg 1950;20:393-417.
40. Cathie IA. Streptomycin-streptokinase treatment of tuberculous meningitis. Lancet 1949;1:441.
41. Hubbard WN Jr. The systemic toxic responses of patients to treatment with streptokinase streptodornase. J Clin Invest 1951;30:1171-4.
42. Johnson AJ, Tillett WS. The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med 1952;95:449-64.
43. Sherry S, Titchener A, Gottesman L, Wasserman P, Troll W. The enzymatic dissolution of experimental arterial thrombi in the dog by trypsin, chymotrypsin and plasminogen activators. J Clin Invest 1954;33:1303-13.
44. Tillett WS, Johnson AJ, McCarty WR. The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. J Clin Invest 1955;34:169-85.
45. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 1958;71:287-96.
46. Fletcher AP, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J Clin Invest 1959;38:1096-110.
47. Fletcher AP, Sherry S, Alkjaersig N, Smyrniotis FE, Jick S. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 1959;38:1111-9.
48. Ruegsegger P, Nydick I, Hutter RC, Freiman AH, Bang NU, Cliffton EE, Ladue JS. Fibrinolytic (plasmin) therapy of experimental coronary thrombi with alteration of the evolution of myocardial infarction. Circulation 1959;19:7-13.
49. Boucek RJ, Murphy WP Jr. Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. Am J Cardiol 1960;6:525-33.
50. Dewar HA, Stephenson P, Horler AR, Cassells-Smith AJ, Ellis PA. Fibrinolytic therapy of coronary thrombosis. Controlled trial of 75 cases. Br Med J 1963;1:915-20.
51. Schmutzler R, Heckner F, Kortge P, van der Loo J, Pezold A, Poliwoda H, et al. Thrombolytic therapy of recent myocardial infarction. I. Introduction, plan of trial, general clinical results. Ger Med Mon 1966;11:308-14.
52. Poliwoda H, Gillmann H, Gebauer D, Kortge P, Schmutzler R, van der Loo J, et al. The thrombolytic therapy of acute myocardial infarction. VI. World Congress of Cardiology Abstracts; 1970. p. 251.
53. Amery A, Roeber G, Vermeulen HJ, Verstraete M. Single-blind randomised multicentre trial comparing heparin and streptokinase treatment in recent myocardial infarction. Acta Med Scand Suppl 1969;505:1-35.
54. Wessler S, Sherman LA. Antiplatelet aggregant agents and thrombolytic compounds in myocardial infarction: current status. Circulation 1972;45:911-8.
55. Dioguardi N, Lotto A, Levi GF, Rota M, Proto C, Mannucci PM, et al. Controlled trial of streptokinase and heparin in acute myocardial infarction. Lancet 1971;2:891-5.
56. Australian multicentre trial of streptokinase in acute myocardial infarction. Med J Aust 1977;1:553.
57. Aber CP, Bass NM, Berry CL, Carson PH, Dobbs RJ, Fox KM, et al. Streptokinase in acute myocardial infarction: a controlled multicentre study in the United Kingdom. Br Med J 1976;2:1100-04.
58. Streptokinase in acute myocardial infarction. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. N Engl J Med 1979;301:797-802.
59. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Kostering H, Oster H, Leitz K. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979;2:354-63.
60. Rentrop P, Blanke H, Karsch KR, Wiegand V, Kostering H, Rahlf G, et al. Reopening of infarct-occluded vessel by transluminal recanalisation and intracoronary streptokinase application (author's transl) [in German]. Dtsch Med Wochenschr 1979;104:1438-40.
61. Laffel GL, Braunwald E. Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction (1). N Engl J Med 1984;311:710-7.
62. Marx M, Levin DC. Coronary thrombolytic therapy: state of the art. AJR Am J Roentgenol 1986;147:1-8.
63. Klugmann S, Della Grazia E, Maras P, Medugno G, Pandullo C, Salvi A, Camerini F. Problems appearing after pharmacologic thrombolysis in acute myocardial infarct [in Italian]. G Ital Cardiol 1983;13:353-6.
64. Verheugt FW, van Eenige MJ, Res JC, Simoons ML, Serruys PW, Vermeer F, et al. Bleeding complications of intracoronary fibrinolytic therapy in acute myocardial infarction. Assessment of risk in a randomised trial. Br Heart J 1985;54:455-9.
65. Spann JF, Sherry S, Carabello BA, Mann RH, McCann WD, Gault JH, et al. High-dose, brief intravenous streptokinase early in acute myocardial infarction. Am Heart J 1982;104(4 Pt 2):939-45.
66. Lew AS, Laramee P, Cercek B, Rodriguez L, Ganz W. Thrombolytic therapy with intracoronary or intravenous streptokinase during acute myocardial infarction. Z Kardiol 1985;74 Suppl 6:129-34.
67. Alderman EL, Jutzy KR, Berte LE, Miller RG, Friedman JP, Creger WP, Eliastam M. Randomized comparison of intravenous versus intracoronary streptokinase for myocardial infarction. Am J Cardiol 1984;54:14-9.
68. Lo YS. Intravenous versus intracoronary streptokinase in acute myocardial infarction. Clin Cardiol 1985;8:609-19.
69. Valentine RP, Pitts DE, Brooks-Brunn JA, Williams JG, Van Hove E, Schmidt PE. Intravenous versus intracoronary strep tokinase in acute myocardial infarction. Am J Cardiol 1985;55:309-12.
70. Verstraete M. Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarction. Eur Heart J 1985;6:586-93.
71. Koren G, Weiss AT, Hasin Y, Appelbaum D, Welber S, Rozenman Y, et al. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Engl J Med 1985;313:1384-9.
72. Hillis LD, Borer J, Braunwald E, Chesebro JH, Cohen LS, Dalen J, et al. High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial. J Am Coll Cardiol 1985;6:957-62.
73. Lew AS, Laramee P, Cercek B, Rodriguez L, Shah PK, Ganz W. The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction. Circulation 1985;72:1053-8.
74. Simoons ML, Serruys PW, vd Brand M, Bar F, de Zwaan C, Res J, et al. Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The Netherlands. Lancet 1985;2:578-82.
75. Burket MW, Smith MR, Walsh TE, Brewster PS, Fraker TD Jr. Relation of effectiveness of intracoronary thrombolysis in acute myocardial infarction to systemic thrombolytic state. Am J Cardiol 1985;56:441-4.
76. Sheehan FH, Mathey DG, Schofer J, Dodge HT, Bolson EL. Factors that determine recovery of left ventricular function after thrombolysis in patients with acute myocardial infarction. Circulation 1985;71:1121-8.
77. Shapiro EP, Brinker JA, Gottlieb SO, Guzman PA, Bulkley BH. Intracoronary thrombolysis 3 to 13 days after acute myocardial infarction for postinfarction angina pectoris. Am J Cardiol 1985;55(13 Pt 1):1453-8.
78. Mayer G, Story WE, Seco JE, Nocero MA Jr, Shaskey DJ, Black MA. Intravenous streptokinase in acute myocardial infarction. Ann Emerg Med 1985;14:410-5.
79. Verani MS, Tortoledo FE, Batty JW, Raizner AE. Effect of coronary artery recanalization on right ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 1985;5:1029-35.
80. Stratton JR, Speck SM, Caldwell JH, Stadius ML, Maynard C, Davis KB, et al. Late effects of intracoronary streptokinase on regional wall motion, ventricular aneurysm and left ventricular thrombus in myocardial infarction: results from the Western Washington Randomized Trial. J Am Coll Cardiol 1985;5:1023-8.
81. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1:397-402.
82. Vermeer F, Simoons ML, Bar FW, Tijssen JG, van Domburg RT, Serruys PW, et al. Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase [published erratum appears in Circulation 1987;75:394]? Circulation 1986;74:1379-89.
83. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1987;2:871-4.
84. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators [published erratum appears in N Engl J Med 1994;330:516]. N Engl J Med 1993;329:1615-22.
85. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1990;336:65-71.
86. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992;339:753-70.
87. Califf RM, White HD, Van de Werf F, Sadowski Z, Armstrong PW, Vahanian A, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation 1996;94:1233-8.
88. Gershlick AH, More RS. Treatment of myocardial infarction. BMJ 1998;316:280-4.
89. Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wilcox RG, et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):549S-575S.
90. Guyatt G, Schunemann HJ, Cook D, Jaeschke R, Pauker S. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl):179S-187S.
91. Diwedi SK, Hiremath JS, Kerkar PG, Reddy KN, Manjunath CN, Ramesh SS, et al. Indigenous recombinant streptokinase vs natural streptokinase in acute myocardial infarction patients: Phase III multicentric randomized double blind trial. Indian J Med Sci 2005;59:200-7.